<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00048074</url>
  </required_header>
  <id_info>
    <org_study_id>BM16550</org_study_id>
    <nct_id>NCT00048074</nct_id>
  </id_info>
  <brief_title>DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis</brief_title>
  <official_title>A Randomized, Double-blind Study Comparing the Effect of Different Treatment Regimens of Intravenous Bonviva on Lumbar Bone Mineral Density in Women With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will assess the efficacy and safety of intravenous administration of Bonviva
      regimens in women with post-menopausal osteoporosis, compared to oral daily administration.
      Patients will also receive daily supplementation with vitamin D and calcium. The anticipated
      time of study treatment is 2+ years, and the target sample size is 500+ individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative Percent Change From Baseline in Mean Bone Mineral Density (BMD) of Lumbar Spine (L2-L4) at 12 Months</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>BMD was measured by a single dual-energy x-ray absorptiometry (DXA) scan of the lumbar spine at the time of screening and at Month 12. The change in BMD was defined as the relative difference between the last individual measurement available at 12 months and Baseline, using the following formula: Relative change = 100 x (BMD at 1 year - BMD at Baseline) / (BMD at Baseline)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative Percent Change From Baseline in Mean BMD of Lumbar Spine (L2-L4) at 24 Months</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>BMD was measured by a single dual-energy x-ray absorptiometry (DXA) scan of the lumbar spine at the time of screening and at Month 24. The change in BMD was defined as the relative difference between the last individual measurement available at 24 months and Baseline, using the following formula: Relative change = 100 x (BMD at 1 year - BMD at Baseline) / (BMD at Baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Mean BMD of Lumbar Spine (L2 - L4) at Month 12 and Month 24</measure>
    <time_frame>Baseline, Month 12 and Month 24</time_frame>
    <description>BMD was measured by a single dual-energy x-ray absorptiometry (DXA) scan of the lumbar spine at screening, Month 12 and Month 24. The absolute change from Baseline in mean BMD of the lumbar spine (L2-L4) was defined as the difference between the last individual measurement available at Month 12 or Month 24 and Baseline. Only participants with data available at particular timepoint were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Percent Change From Baseline in BMD of Proximal Femur (Consisting of Total Hip, Trochanter, and Femoral Neck) at Month 12 and 24</measure>
    <time_frame>Baseline, Month 12 and Month 24</time_frame>
    <description>BMD was measured by a single DXA scan of the proximal femur at the time of screening, Month 12 and Month 24.The change in BMD of the proximal femur (total hip, trochanter, femoral neck) was defined as the relative difference between the last individual measurement available at Month 12 or Month 24and Baseline, using the following formula: Relative change = 100 x (BMD at 1 year/2year - BMD at Baseline) / (BMD at Baseline). BMD of fractured bones that could impact the scan area were not taken into account. Only participants with data available at particular timepoint were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in BMD of Proximal Femur (Consisting of Total Hip, Trochanter, and Femoral Neck) at Month 12 and 24</measure>
    <time_frame>Baseline, Month 12 and Month 24</time_frame>
    <description>BMD was measured by a single DXA scan of the proximal femur at the time of screening, Month 12 and Month 24. The absolute change in BMD was defined as the difference between the last individual measurement available at Month 12 or Month 24 and Baseline. BMD of fractured bones that could impact the scan area were not taken into account. Only participants with data available at particular timepoint were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change From Baseline in Serum C-telopeptide of Alpha-chain of Type I Collagen (CTX) at Month 6, 12, and 24</measure>
    <time_frame>Baseline, At Month 6, 12, and 24.</time_frame>
    <description>Serum CTX, a biochemical marker of bone resorption, was measured using the Elecsys s-CTX-I assay, an electrochemiluminescence immunoassay (ECLIA) technique. Samples for serum CTX measurements were collected from participants immediately prior to their IV dosing. Thus, the values reported here represent trough or residual values taken at the end of the 2 month or 3 month IV dosing interval. The change in serum CTX was defined as the relative difference between the last individual measurement available at Month 6 or Month 12 or Month 24 and Baseline, using the following formula: Relative change = 100 x (CTX at Month 6/Month 12/Month 24- CTX at Baseline) / (CTX at Baseline). Only participants with data available at particular timepoint were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Serum CTX at Month 6, 12, and 24</measure>
    <time_frame>Baseline, At Month 6, 12, and 24.</time_frame>
    <description>Serum CTX, a biochemical marker of bone resorption, was measured using the Elecsys s-CTX-I assay, an electrochemiluminescence immunoassay (ECLIA) technique. Samples for serum CTX measurements were collected from participants immediately prior to their IV dosing. Thus, the values reported here represent trough or residual values taken at the end of the 2 month or 3 month IV dosing interval. The absolute change from Baseline in serum CTX was defined as the difference between the last individual measurement available at Month 6 or Month 12 or Month 24 and Baseline. Only participants with data available at particular timepoint were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Mean Lumbar Spine (L2 - L4) BMD Above or Equal to Baseline at Month 12 and 24</measure>
    <time_frame>At Month 12 and 24</time_frame>
    <description>A participant is a responder if the mean lumber spine (L2 - L4) BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Total Hip BMD Above or Equal to Baseline at Month 12 and 24</measure>
    <time_frame>At Month 12 and 24</time_frame>
    <description>A participant is a responder if the mean total hip BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Trochanter BMD Above or Equal to Baseline at Month 12 and 24</measure>
    <time_frame>At Month 12 and 24</time_frame>
    <description>A participant is a responder if the mean trochanter BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Femoral Neck BMD Above or Equal to Baseline at Month 12 and 24</measure>
    <time_frame>At Month 12 and 24</time_frame>
    <description>A participant is a responder if the mean femoral neck BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Mean Total Hip and Lumbar Spine BMD Above or Equal to Baseline at Month 12 and 24</measure>
    <time_frame>At Month 12 and 24</time_frame>
    <description>A participant is a responder if the mean total hip and mean lumbar spine BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Mean Trochanter and Lumbar Spine BMD Above or Equal to Baseline at Month 12 and 24</measure>
    <time_frame>At Month 12 and 24</time_frame>
    <description>A participant is a responder if the mean trochanter and lumbar spine BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Mean Femoral Neck and Lumbar Spine BMD Above or Equal to Baseline at Month 12 and 24</measure>
    <time_frame>At Month 12 and 24</time_frame>
    <description>A participant is a responder if the mean femoral neck and lumbar spine BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Any Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>An AE is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Marked Abnormality in Laboratory Parameters</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Marked laboratory test value abnormalities (high and low) are those which exceed the marked reference range (i.e., a reference range greater than the standard reference range) and which also represents a clinically relevant change from baseline of at least a designated amount. The indicated abnormal laboratory parameters (along with their marked reference range) are as follows: low and high Hematocrit (0.36 - 0.60 fraction), low and high hemoglobin (11.0 - 20.0 g/dL), low and high platelets (100 - 700 * 10^9/L), low and high white blood cell (WBC) (3.0 - 18.0 * 10^9/L), high alanine aminotransferase (ALAT) (0 - 60 U/L), high blood urea nitrogen (BUN) (0 - 14.3 mmol/L) , high creatinine (0 - 154 mmol/L), low albumin (27.0 - 48.0 g/L), low and high chloride (95 - 115 mmol/L), low potassium (3.0 - 6.0 mmol/L), low sodium (130 - 150 mmol/L), high calcium (2.00 - 2.90 mmol/L), low and high phosphate (0.75 - 1.60 mmol/L).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1395</enrollment>
  <condition>Post Menopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral placebo daily and IV ibandronate 2 mg q 2 mo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral ibandronate 2.5 mg daily and IV placebo q 2 mo and q 3 mo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral placebo daily and IV ibandronate 3 mg q 3 mo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibandronate [Bonviva/Boniva]</intervention_name>
    <description>2mg iv every 2 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibandronate [Bonviva/Boniva]</intervention_name>
    <description>2.5mg po daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibandronate [Bonviva/Boniva]</intervention_name>
    <description>3mg iv every 3 months</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women 55-80 years of age;

          -  post-menopausal for &gt;=5 years;

          -  ambulatory.

        Exclusion Criteria:

          -  malignant disease diagnosed within the previous 10 years (except basal cell cancer
             that has been successfully removed);

          -  breast cancer within the previous 20 years;

          -  allergy to bisphosphonates;

          -  previous treatment with an intravenous bisphosphonate at any time;

          -  previous treatment with an oral bisphosphonate within the last 6 months, &gt;1 month of
             treatment within the last year, or &gt;3 months of treatment within the last 2 years.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205-7199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <zip>34748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coeur D'alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darlinghurst</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nedlands</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Leonards</city>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <zip>3129</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1180</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <zip>4020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7T 2P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 0H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plzen</city>
        <zip>305 99</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <zip>128 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>København</city>
        <zip>1399</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Århus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orleans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bochum</city>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arenzano</city>
        <zip>16011</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valeggio Sul Mincio</city>
        <zip>37067</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <zip>11000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haugesund</city>
        <zip>5507</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0176</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stavanger</city>
        <zip>4010</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grudziadz</city>
        <zip>86-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sommerset West</city>
        <zip>7129</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 1LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2002</study_first_submitted>
  <study_first_submitted_qc>October 24, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2002</study_first_posted>
  <results_first_submitted>January 4, 2016</results_first_submitted>
  <results_first_submitted_qc>January 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2016</results_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibandronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 1804 participants were screened for the study, from which 1395 participants were enrolled and randomized into treatment with ibandronate. The trial was conducted at 58 centers in 16 countries from June 2002 to May 2005.</recruitment_details>
      <pre_assignment_details>Out of the 1395 participants who were randomized into the study, only 1382 participants received at least one dose of trial treatment and had at least one follow-up assessment as 4 participants did not have safety follow-up and 9 participants did not receive trial treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ibandronate 2.5mg Daily</title>
          <description>Participants received 2.5 milligrams (mg) of ibandronate orally daily and IV placebo injection at intervals of either 2 or 3 months for a total treatment period of 24 months.</description>
        </group>
        <group group_id="P2">
          <title>Ibandronate 2mg q 2 mo IV</title>
          <description>Participants received 2 mg of ibandronate intravenously (IV) every two months and placebo tablet daily for a total treatment period of 24 months.</description>
        </group>
        <group group_id="P3">
          <title>Ibandronate 3mg q 3 mo IV</title>
          <description>Participants received 3 mg of ibandronate IV every three months and placebo tablet daily for a total treatment period of 24 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="465"/>
                <participants group_id="P2" count="448"/>
                <participants group_id="P3" count="469"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="384"/>
                <participants group_id="P2" count="361"/>
                <participants group_id="P3" count="372"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="97"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="53"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study participation was terminated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Husband ill</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Out of station</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Social reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population: All participants who were randomized and had at least one dose of study drug, whether withdrawn prematurely or not, and who had at least one follow-up data point were included.</population>
      <group_list>
        <group group_id="B1">
          <title>Ibandronate 2.5mg Daily</title>
          <description>Participants received 2.5 milligrams (mg) of ibandronate orally daily and IV placebo injection at intervals of either 2 or 3 months for a total treatment period of 24 months.</description>
        </group>
        <group group_id="B2">
          <title>Ibandronate 2mg q 2 mo IV</title>
          <description>Participants received 2 mg of ibandronate intravenously (IV) every two months and placebo tablet daily for a total treatment period of 24 months.</description>
        </group>
        <group group_id="B3">
          <title>Ibandronate 3mg q 3 mo IV</title>
          <description>Participants received 3 mg of ibandronate IV every three months and placebo tablet daily for a total treatment period of 24 months.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="465"/>
            <count group_id="B2" value="448"/>
            <count group_id="B3" value="469"/>
            <count group_id="B4" value="1382"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.7" spread="6.08"/>
                    <measurement group_id="B2" value="66.6" spread="6.26"/>
                    <measurement group_id="B3" value="65.8" spread="6.30"/>
                    <measurement group_id="B4" value="66.0" spread="6.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="465"/>
                    <measurement group_id="B2" value="448"/>
                    <measurement group_id="B3" value="469"/>
                    <measurement group_id="B4" value="1382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relative Percent Change From Baseline in Mean Bone Mineral Density (BMD) of Lumbar Spine (L2-L4) at 12 Months</title>
        <description>BMD was measured by a single dual-energy x-ray absorptiometry (DXA) scan of the lumbar spine at the time of screening and at Month 12. The change in BMD was defined as the relative difference between the last individual measurement available at 12 months and Baseline, using the following formula: Relative change = 100 x (BMD at 1 year - BMD at Baseline) / (BMD at Baseline)</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5mg Daily</title>
            <description>Participants received 2.5 milligrams (mg) of ibandronate orally daily and IV placebo injection at intervals of either 2 or 3 months for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 2mg q 2 mo IV</title>
            <description>Participants received 2 mg of ibandronate intravenously (IV) every two months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 3mg q 3 mo IV</title>
            <description>Participants received 3 mg of ibandronate IV every three months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Percent Change From Baseline in Mean Bone Mineral Density (BMD) of Lumbar Spine (L2-L4) at 12 Months</title>
          <description>BMD was measured by a single dual-energy x-ray absorptiometry (DXA) scan of the lumbar spine at the time of screening and at Month 12. The change in BMD was defined as the relative difference between the last individual measurement available at 12 months and Baseline, using the following formula: Relative change = 100 x (BMD at 1 year - BMD at Baseline) / (BMD at Baseline)</description>
          <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="359"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8199" spread="3.8576"/>
                    <measurement group_id="O2" value="5.0872" spread="3.8746"/>
                    <measurement group_id="O3" value="4.8188" spread="3.7613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary hypothesis was that the difference in the effects of daily oral ibandronate and IV ibandronate (2mg q 2 mo IV) on the relative change in lumbar spine BMD (L2 – L4) was small, no more than 1%, the margin of clinical equivalence.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The IV dosing regimen (2mg q 2 mo IV) was considered non-inferior to the 2.5 mg daily regimen if the lower bound of the two-sided 95% CI on the difference in mean percent change in BMD was greater or equal to –1 percentage point.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.257</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.701</ci_lower_limit>
            <ci_upper_limit>1.814</ci_upper_limit>
            <estimate_desc>Treatment effect is the difference in the mean values of the IV regimen (2mg q 2 mo IV) and the active-control.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary hypothesis was that the difference in the effects of daily oral ibandronate and IV ibandronate (3mg q 3 mo IV) on the relative change in lumbar spine BMD (L2 – L4) was small, no more than 1%, the margin of clinical equivalence.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The IV dosing regimen (3mg q 3 mo IV) was considered non-inferior to the 2.5 mg daily regimen if the lower bound of the two-sided 95% CI on the difference in mean percent change in BMD was greater or equal to –1 percentage point.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.025</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.471</ci_lower_limit>
            <ci_upper_limit>1.578</ci_upper_limit>
            <estimate_desc>Treatment effect is the difference in the mean values of the IV regimen (3mg q 3 mo IV) and the active-control.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Percent Change From Baseline in Mean BMD of Lumbar Spine (L2-L4) at 24 Months</title>
        <description>BMD was measured by a single dual-energy x-ray absorptiometry (DXA) scan of the lumbar spine at the time of screening and at Month 24. The change in BMD was defined as the relative difference between the last individual measurement available at 24 months and Baseline, using the following formula: Relative change = 100 x (BMD at 1 year - BMD at Baseline) / (BMD at Baseline)</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5mg Daily</title>
            <description>Participants received 2.5 milligrams (mg) of ibandronate orally daily and IV placebo injection at intervals of either 2 or 3 months for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 2mg q 2 mo IV</title>
            <description>Participants received 2 mg of ibandronate intravenously (IV) every two months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 3mg q 3 mo IV</title>
            <description>Participants received 3 mg of ibandronate IV every three months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Percent Change From Baseline in Mean BMD of Lumbar Spine (L2-L4) at 24 Months</title>
          <description>BMD was measured by a single dual-energy x-ray absorptiometry (DXA) scan of the lumbar spine at the time of screening and at Month 24. The change in BMD was defined as the relative difference between the last individual measurement available at 24 months and Baseline, using the following formula: Relative change = 100 x (BMD at 1 year - BMD at Baseline) / (BMD at Baseline)</description>
          <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="320"/>
                <count group_id="O3" value="334"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8412" spread="4.8654"/>
                    <measurement group_id="O2" value="6.3999" spread="4.7392"/>
                    <measurement group_id="O3" value="6.2777" spread="5.0049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Mean BMD of Lumbar Spine (L2 – L4) at Month 12 and Month 24</title>
        <description>BMD was measured by a single dual-energy x-ray absorptiometry (DXA) scan of the lumbar spine at screening, Month 12 and Month 24. The absolute change from Baseline in mean BMD of the lumbar spine (L2-L4) was defined as the difference between the last individual measurement available at Month 12 or Month 24 and Baseline. Only participants with data available at particular timepoint were analyzed.</description>
        <time_frame>Baseline, Month 12 and Month 24</time_frame>
        <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5mg Daily</title>
            <description>Participants received 2.5 milligrams (mg) of ibandronate orally daily and IV placebo injection at intervals of either 2 or 3 months for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 2mg q 2 mo IV</title>
            <description>Participants received 2 mg of ibandronate intravenously (IV) every two months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 3mg q 3 mo IV</title>
            <description>Participants received 3 mg of ibandronate IV every three months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Mean BMD of Lumbar Spine (L2 – L4) at Month 12 and Month 24</title>
          <description>BMD was measured by a single dual-energy x-ray absorptiometry (DXA) scan of the lumbar spine at screening, Month 12 and Month 24. The absolute change from Baseline in mean BMD of the lumbar spine (L2-L4) was defined as the difference between the last individual measurement available at Month 12 or Month 24 and Baseline. Only participants with data available at particular timepoint were analyzed.</description>
          <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
          <units>Absolute Change (g/cm^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12, n= 368, 350, 359</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.028" spread="0.0287"/>
                    <measurement group_id="O2" value="0.037" spread="0.0282"/>
                    <measurement group_id="O3" value="0.035" spread="0.0269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, n= 334, 320, 334</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.036" spread="0.0361"/>
                    <measurement group_id="O2" value="0.047" spread="0.0347"/>
                    <measurement group_id="O3" value="0.046" spread="0.0357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Percent Change From Baseline in BMD of Proximal Femur (Consisting of Total Hip, Trochanter, and Femoral Neck) at Month 12 and 24</title>
        <description>BMD was measured by a single DXA scan of the proximal femur at the time of screening, Month 12 and Month 24.The change in BMD of the proximal femur (total hip, trochanter, femoral neck) was defined as the relative difference between the last individual measurement available at Month 12 or Month 24and Baseline, using the following formula: Relative change = 100 x (BMD at 1 year/2year - BMD at Baseline) / (BMD at Baseline). BMD of fractured bones that could impact the scan area were not taken into account. Only participants with data available at particular timepoint were analyzed.</description>
        <time_frame>Baseline, Month 12 and Month 24</time_frame>
        <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5mg Daily</title>
            <description>Participants received 2.5 milligrams (mg) of ibandronate orally daily and IV placebo injection at intervals of either 2 or 3 months for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 2mg q 2 mo IV</title>
            <description>Participants received 2 mg of ibandronate intravenously (IV) every two months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 3mg q 3 mo IV</title>
            <description>Participants received 3 mg of ibandronate IV every three months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Percent Change From Baseline in BMD of Proximal Femur (Consisting of Total Hip, Trochanter, and Femoral Neck) at Month 12 and 24</title>
          <description>BMD was measured by a single DXA scan of the proximal femur at the time of screening, Month 12 and Month 24.The change in BMD of the proximal femur (total hip, trochanter, femoral neck) was defined as the relative difference between the last individual measurement available at Month 12 or Month 24and Baseline, using the following formula: Relative change = 100 x (BMD at 1 year/2year - BMD at Baseline) / (BMD at Baseline). BMD of fractured bones that could impact the scan area were not taken into account. Only participants with data available at particular timepoint were analyzed.</description>
          <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total hip, Month 12, n = 364, 343, 357</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7857" spread="2.8171"/>
                    <measurement group_id="O2" value="2.5150" spread="2.6737"/>
                    <measurement group_id="O3" value="2.3604" spread="3.5156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total hip , Month 24, n = 330, 316, 333</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2011" spread="3.6997"/>
                    <measurement group_id="O2" value="3.3699" spread="2.9749"/>
                    <measurement group_id="O3" value="3.1279" spread="4.5422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trochanter, Month 12, n = 364, 343, 357</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9721" spread="4.1651"/>
                    <measurement group_id="O2" value="4.0275" spread="3.8890"/>
                    <measurement group_id="O3" value="3.8144" spread="6.0921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trochanter, Month 24, n = 330, 316, 333</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4669" spread="4.7241"/>
                    <measurement group_id="O2" value="5.0428" spread="4.4640"/>
                    <measurement group_id="O3" value="4.9165" spread="7.5057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral neck, Month 12, n = 364, 343, 357</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6129" spread="4.1050"/>
                    <measurement group_id="O2" value="1.9700" spread="3.5537"/>
                    <measurement group_id="O3" value="2.3055" spread="3.9283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral neck, Month 24, n = 330, 316, 333</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2457" spread="4.3015"/>
                    <measurement group_id="O2" value="2.7449" spread="4.1996"/>
                    <measurement group_id="O3" value="2.7849" spread="4.6723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in BMD of Proximal Femur (Consisting of Total Hip, Trochanter, and Femoral Neck) at Month 12 and 24</title>
        <description>BMD was measured by a single DXA scan of the proximal femur at the time of screening, Month 12 and Month 24. The absolute change in BMD was defined as the difference between the last individual measurement available at Month 12 or Month 24 and Baseline. BMD of fractured bones that could impact the scan area were not taken into account. Only participants with data available at particular timepoint were analyzed.</description>
        <time_frame>Baseline, Month 12 and Month 24</time_frame>
        <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5mg Daily</title>
            <description>Participants received 2.5 milligrams (mg) of ibandronate orally daily and IV placebo injection at intervals of either 2 or 3 months for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 2mg q 2 mo IV</title>
            <description>Participants received 2 mg of ibandronate intravenously (IV) every two months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 3mg q 3 mo IV</title>
            <description>Participants received 3 mg of ibandronate IV every three months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in BMD of Proximal Femur (Consisting of Total Hip, Trochanter, and Femoral Neck) at Month 12 and 24</title>
          <description>BMD was measured by a single DXA scan of the proximal femur at the time of screening, Month 12 and Month 24. The absolute change in BMD was defined as the difference between the last individual measurement available at Month 12 or Month 24 and Baseline. BMD of fractured bones that could impact the scan area were not taken into account. Only participants with data available at particular timepoint were analyzed.</description>
          <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
          <units>Absolute Change (g/cm^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total hip, Month 12, n = 364, 343, 357</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.013" spread="0.0202"/>
                    <measurement group_id="O2" value="0.018" spread="0.0192"/>
                    <measurement group_id="O3" value="0.016" spread="0.0213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total hip, Month 24, n = 330, 316, 333</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.015" spread="0.0259"/>
                    <measurement group_id="O2" value="0.025" spread="0.0211"/>
                    <measurement group_id="O3" value="0.022" spread="0.0278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trochanter, Month 12, n = 364, 343, 357</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.016" spread="0.0229"/>
                    <measurement group_id="O2" value="0.022" spread="0.0209"/>
                    <measurement group_id="O3" value="0.020" spread="0.0250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trochanter, Month 24, n = 330, 316, 333</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.019" spread="0.0256"/>
                    <measurement group_id="O2" value="0.029" spread="0.0242"/>
                    <measurement group_id="O3" value="0.026" spread="0.0322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral neck , Month 12, n = 364, 343, 357</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" spread="0.0243"/>
                    <measurement group_id="O2" value="0.013" spread="0.0227"/>
                    <measurement group_id="O3" value="0.014" spread="0.0240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral neck , Month 24, n = 330, 316, 333</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.014" spread="0.0258"/>
                    <measurement group_id="O2" value="0.018" spread="0.0279"/>
                    <measurement group_id="O3" value="0.018" spread="0.0278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change From Baseline in Serum C-telopeptide of Alpha-chain of Type I Collagen (CTX) at Month 6, 12, and 24</title>
        <description>Serum CTX, a biochemical marker of bone resorption, was measured using the Elecsys s-CTX-I assay, an electrochemiluminescence immunoassay (ECLIA) technique. Samples for serum CTX measurements were collected from participants immediately prior to their IV dosing. Thus, the values reported here represent trough or residual values taken at the end of the 2 month or 3 month IV dosing interval. The change in serum CTX was defined as the relative difference between the last individual measurement available at Month 6 or Month 12 or Month 24 and Baseline, using the following formula: Relative change = 100 x (CTX at Month 6/Month 12/Month 24- CTX at Baseline) / (CTX at Baseline). Only participants with data available at particular timepoint were analyzed.</description>
        <time_frame>Baseline, At Month 6, 12, and 24.</time_frame>
        <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5mg Daily</title>
            <description>Participants received 2.5 milligrams (mg) of ibandronate orally daily and IV placebo injection at intervals of either 2 or 3 months for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 2mg q 2 mo IV</title>
            <description>Participants received 2 mg of ibandronate intravenously (IV) every two months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 3mg q 3 mo IV</title>
            <description>Participants received 3 mg of ibandronate IV every three months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change From Baseline in Serum C-telopeptide of Alpha-chain of Type I Collagen (CTX) at Month 6, 12, and 24</title>
          <description>Serum CTX, a biochemical marker of bone resorption, was measured using the Elecsys s-CTX-I assay, an electrochemiluminescence immunoassay (ECLIA) technique. Samples for serum CTX measurements were collected from participants immediately prior to their IV dosing. Thus, the values reported here represent trough or residual values taken at the end of the 2 month or 3 month IV dosing interval. The change in serum CTX was defined as the relative difference between the last individual measurement available at Month 6 or Month 12 or Month 24 and Baseline, using the following formula: Relative change = 100 x (CTX at Month 6/Month 12/Month 24- CTX at Baseline) / (CTX at Baseline). Only participants with data available at particular timepoint were analyzed.</description>
          <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6, n = 358, 342, 345</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.715" spread="30.2820"/>
                    <measurement group_id="O2" value="-55.539" spread="42.6206"/>
                    <measurement group_id="O3" value="-51.196" spread="31.0579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, n = 360, 342, 347</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.387" spread="33.2810"/>
                    <measurement group_id="O2" value="-48.042" spread="95.3711"/>
                    <measurement group_id="O3" value="-49.873" spread="36.0415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, n = 310, 301, 298</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.549" spread="35.0888"/>
                    <measurement group_id="O2" value="-41.338" spread="76.8201"/>
                    <measurement group_id="O3" value="-44.325" spread="38.1338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Serum CTX at Month 6, 12, and 24</title>
        <description>Serum CTX, a biochemical marker of bone resorption, was measured using the Elecsys s-CTX-I assay, an electrochemiluminescence immunoassay (ECLIA) technique. Samples for serum CTX measurements were collected from participants immediately prior to their IV dosing. Thus, the values reported here represent trough or residual values taken at the end of the 2 month or 3 month IV dosing interval. The absolute change from Baseline in serum CTX was defined as the difference between the last individual measurement available at Month 6 or Month 12 or Month 24 and Baseline. Only participants with data available at particular timepoint were analyzed.</description>
        <time_frame>Baseline, At Month 6, 12, and 24.</time_frame>
        <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5mg Daily</title>
            <description>Participants received 2.5 milligrams (mg) of ibandronate orally daily and IV placebo injection at intervals of either 2 or 3 months for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 2mg q 2 mo IV</title>
            <description>Participants received 2 mg of ibandronate intravenously (IV) every two months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 3mg q 3 mo IV</title>
            <description>Participants received 3 mg of ibandronate IV every three months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Serum CTX at Month 6, 12, and 24</title>
          <description>Serum CTX, a biochemical marker of bone resorption, was measured using the Elecsys s-CTX-I assay, an electrochemiluminescence immunoassay (ECLIA) technique. Samples for serum CTX measurements were collected from participants immediately prior to their IV dosing. Thus, the values reported here represent trough or residual values taken at the end of the 2 month or 3 month IV dosing interval. The absolute change from Baseline in serum CTX was defined as the difference between the last individual measurement available at Month 6 or Month 12 or Month 24 and Baseline. Only participants with data available at particular timepoint were analyzed.</description>
          <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
          <units>Absolute Change (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6, n = 358, 342, 345</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.318" spread="0.2550"/>
                    <measurement group_id="O2" value="-0.322" spread="0.2015"/>
                    <measurement group_id="O3" value="-0.281" spread="0.2018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, n = 360, 342, 347</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.321" spread="0.2624"/>
                    <measurement group_id="O2" value="-0.318" spread="0.2239"/>
                    <measurement group_id="O3" value="-0.290" spread="0.2196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, n = 310, 301, 298</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.324" spread="0.2693"/>
                    <measurement group_id="O2" value="-0.285" spread="0.2092"/>
                    <measurement group_id="O3" value="-0.276" spread="0.2323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Mean Lumbar Spine (L2 – L4) BMD Above or Equal to Baseline at Month 12 and 24</title>
        <description>A participant is a responder if the mean lumber spine (L2 – L4) BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
        <time_frame>At Month 12 and 24</time_frame>
        <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5mg Daily</title>
            <description>Participants received 2.5 milligrams (mg) of ibandronate orally daily and IV placebo injection at intervals of either 2 or 3 months for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 2mg q 2 mo IV</title>
            <description>Participants received 2 mg of ibandronate intravenously (IV) every two months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 3mg q 3 mo IV</title>
            <description>Participants received 3 mg of ibandronate IV every three months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Mean Lumbar Spine (L2 – L4) BMD Above or Equal to Baseline at Month 12 and 24</title>
          <description>A participant is a responder if the mean lumber spine (L2 – L4) BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
          <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Above baseline, Month 12, n = 368, 350, 359</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.1"/>
                    <measurement group_id="O2" value="92.3"/>
                    <measurement group_id="O3" value="91.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Above baseline, Month 24, n = 334, 320, 334</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.7"/>
                    <measurement group_id="O2" value="92.8"/>
                    <measurement group_id="O3" value="92.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Total Hip BMD Above or Equal to Baseline at Month 12 and 24</title>
        <description>A participant is a responder if the mean total hip BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
        <time_frame>At Month 12 and 24</time_frame>
        <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5mg Daily</title>
            <description>Participants received 2.5 milligrams (mg) of ibandronate orally daily and IV placebo injection at intervals of either 2 or 3 months for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 2mg q 2 mo IV</title>
            <description>Participants received 2 mg of ibandronate intravenously (IV) every two months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 3mg q 3 mo IV</title>
            <description>Participants received 3 mg of ibandronate IV every three months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Total Hip BMD Above or Equal to Baseline at Month 12 and 24</title>
          <description>A participant is a responder if the mean total hip BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
          <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Above baseline, Month 12, n = 364, 343, 357</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5"/>
                    <measurement group_id="O2" value="86.0"/>
                    <measurement group_id="O3" value="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Above baseline, Month 24, n = 330, 316, 333</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0"/>
                    <measurement group_id="O2" value="88.6"/>
                    <measurement group_id="O3" value="85.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Trochanter BMD Above or Equal to Baseline at Month 12 and 24</title>
        <description>A participant is a responder if the mean trochanter BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
        <time_frame>At Month 12 and 24</time_frame>
        <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5mg Daily</title>
            <description>Participants received 2.5 milligrams (mg) of ibandronate orally daily and IV placebo injection at intervals of either 2 or 3 months for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 2mg q 2 mo IV</title>
            <description>Participants received 2 mg of ibandronate intravenously (IV) every two months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 3mg q 3 mo IV</title>
            <description>Participants received 3 mg of ibandronate IV every three months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Trochanter BMD Above or Equal to Baseline at Month 12 and 24</title>
          <description>A participant is a responder if the mean trochanter BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
          <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Above baseline, Month 12, n = 364, 343, 357</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6"/>
                    <measurement group_id="O2" value="88.6"/>
                    <measurement group_id="O3" value="86.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Above baseline, Month 24, n = 330, 316, 333</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="92.1"/>
                    <measurement group_id="O3" value="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Femoral Neck BMD Above or Equal to Baseline at Month 12 and 24</title>
        <description>A participant is a responder if the mean femoral neck BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
        <time_frame>At Month 12 and 24</time_frame>
        <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5mg Daily</title>
            <description>Participants received 2.5 milligrams (mg) of ibandronate orally daily and IV placebo injection at intervals of either 2 or 3 months for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 2mg q 2 mo IV</title>
            <description>Participants received 2 mg of ibandronate intravenously (IV) every two months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 3mg q 3 mo IV</title>
            <description>Participants received 3 mg of ibandronate IV every three months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Femoral Neck BMD Above or Equal to Baseline at Month 12 and 24</title>
          <description>A participant is a responder if the mean femoral neck BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
          <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Above baseline, Month 12, n = 364, 343, 357</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.1"/>
                    <measurement group_id="O2" value="74.1"/>
                    <measurement group_id="O3" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Above baseline, Month 24, n = 330, 316, 333</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.6"/>
                    <measurement group_id="O2" value="77.5"/>
                    <measurement group_id="O3" value="76.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Mean Total Hip and Lumbar Spine BMD Above or Equal to Baseline at Month 12 and 24</title>
        <description>A participant is a responder if the mean total hip and mean lumbar spine BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
        <time_frame>At Month 12 and 24</time_frame>
        <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5mg Daily</title>
            <description>Participants received 2.5 milligrams (mg) of ibandronate orally daily and IV placebo injection at intervals of either 2 or 3 months for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 2mg q 2 mo IV</title>
            <description>Participants received 2 mg of ibandronate intravenously (IV) every two months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 3mg q 3 mo IV</title>
            <description>Participants received 3 mg of ibandronate IV every three months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Mean Total Hip and Lumbar Spine BMD Above or Equal to Baseline at Month 12 and 24</title>
          <description>A participant is a responder if the mean total hip and mean lumbar spine BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
          <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Above baseline, Month 12, n = 363, 343, 355</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9"/>
                    <measurement group_id="O2" value="80.5"/>
                    <measurement group_id="O3" value="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Above baseline, Month 24, n = 330, 314, 332</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8"/>
                    <measurement group_id="O2" value="83.1"/>
                    <measurement group_id="O3" value="80.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Mean Trochanter and Lumbar Spine BMD Above or Equal to Baseline at Month 12 and 24</title>
        <description>A participant is a responder if the mean trochanter and lumbar spine BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
        <time_frame>At Month 12 and 24</time_frame>
        <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5mg Daily</title>
            <description>Participants received 2.5 milligrams (mg) of ibandronate orally daily and IV placebo injection at intervals of either 2 or 3 months for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 2mg q 2 mo IV</title>
            <description>Participants received 2 mg of ibandronate intravenously (IV) every two months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 3mg q 3 mo IV</title>
            <description>Participants received 3 mg of ibandronate IV every three months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Mean Trochanter and Lumbar Spine BMD Above or Equal to Baseline at Month 12 and 24</title>
          <description>A participant is a responder if the mean trochanter and lumbar spine BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
          <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Above baseline, Month 12, n = 363, 343, 355</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0"/>
                    <measurement group_id="O2" value="83.4"/>
                    <measurement group_id="O3" value="79.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Above baseline, Month 24, n = 330, 314, 332</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9"/>
                    <measurement group_id="O2" value="85.7"/>
                    <measurement group_id="O3" value="83.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Mean Femoral Neck and Lumbar Spine BMD Above or Equal to Baseline at Month 12 and 24</title>
        <description>A participant is a responder if the mean femoral neck and lumbar spine BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
        <time_frame>At Month 12 and 24</time_frame>
        <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5mg Daily</title>
            <description>Participants received 2.5 milligrams (mg) of ibandronate orally daily and IV placebo injection at intervals of either 2 or 3 months for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 2mg q 2 mo IV</title>
            <description>Participants received 2 mg of ibandronate intravenously (IV) every two months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 3mg q 3 mo IV</title>
            <description>Participants received 3 mg of ibandronate IV every three months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Mean Femoral Neck and Lumbar Spine BMD Above or Equal to Baseline at Month 12 and 24</title>
          <description>A participant is a responder if the mean femoral neck and lumbar spine BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.</description>
          <population>Per protocol population: Participants who were randomized, received at least one dose of study medication and had at least one efficacy (BMD or serum CTX) follow-up data point and did not have any major violations of the protocol.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Above baseline, Month 12, n = 363, 343, 355</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.4"/>
                    <measurement group_id="O2" value="69.4"/>
                    <measurement group_id="O3" value="64.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Above baseline, Month 24, n = 330, 314, 332</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.7"/>
                    <measurement group_id="O2" value="72.3"/>
                    <measurement group_id="O3" value="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Any Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
        <description>An AE is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.</description>
        <time_frame>Approximately 2 years</time_frame>
        <population>Safety Population: All participants who were randomized and had at least one dose of study drug, whether withdrawn prematurely or not, and who had at least one follow-up data point.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5mg Daily</title>
            <description>Participants received 2.5 milligrams (mg) of ibandronate orally daily and IV placebo injection at intervals of either 2 or 3 months for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 2mg q 2 mo IV</title>
            <description>Participants received 2 mg of ibandronate intravenously (IV) every two months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 3mg q 3 mo IV</title>
            <description>Participants received 3 mg of ibandronate IV every three months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Any Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
          <description>An AE is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.</description>
          <population>Safety Population: All participants who were randomized and had at least one dose of study drug, whether withdrawn prematurely or not, and who had at least one follow-up data point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="465"/>
                <count group_id="O2" value="448"/>
                <count group_id="O3" value="469"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408"/>
                    <measurement group_id="O2" value="397"/>
                    <measurement group_id="O3" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Marked Abnormality in Laboratory Parameters</title>
        <description>Marked laboratory test value abnormalities (high and low) are those which exceed the marked reference range (i.e., a reference range greater than the standard reference range) and which also represents a clinically relevant change from baseline of at least a designated amount. The indicated abnormal laboratory parameters (along with their marked reference range) are as follows: low and high Hematocrit (0.36 - 0.60 fraction), low and high hemoglobin (11.0 - 20.0 g/dL), low and high platelets (100 – 700 * 10^9/L), low and high white blood cell (WBC) (3.0 - 18.0 * 10^9/L), high alanine aminotransferase (ALAT) (0 – 60 U/L), high blood urea nitrogen (BUN) (0 - 14.3 mmol/L) , high creatinine (0 – 154 mmol/L), low albumin (27.0 - 48.0 g/L), low and high chloride (95 – 115 mmol/L), low potassium (3.0 - 6.0 mmol/L), low sodium (130 – 150 mmol/L), high calcium (2.00 - 2.90 mmol/L), low and high phosphate (0.75 - 1.60 mmol/L).</description>
        <time_frame>Approximately 2 years</time_frame>
        <population>Safety Population: All participants who were randomized and had at least one dose of study drug, whether withdrawn prematurely or not, and who had at least one follow-up data point. Only participants with data available for the indicated laboratory abnormality were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5mg Daily</title>
            <description>Participants received 2.5 milligrams (mg) of ibandronate orally daily and IV placebo injection at intervals of either 2 or 3 months for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 2mg q 2 mo IV</title>
            <description>Participants received 2 mg of ibandronate intravenously (IV) every two months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 3mg q 3 mo IV</title>
            <description>Participants received 3 mg of ibandronate IV every three months and placebo tablet daily for a total treatment period of 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Marked Abnormality in Laboratory Parameters</title>
          <description>Marked laboratory test value abnormalities (high and low) are those which exceed the marked reference range (i.e., a reference range greater than the standard reference range) and which also represents a clinically relevant change from baseline of at least a designated amount. The indicated abnormal laboratory parameters (along with their marked reference range) are as follows: low and high Hematocrit (0.36 - 0.60 fraction), low and high hemoglobin (11.0 - 20.0 g/dL), low and high platelets (100 – 700 * 10^9/L), low and high white blood cell (WBC) (3.0 - 18.0 * 10^9/L), high alanine aminotransferase (ALAT) (0 – 60 U/L), high blood urea nitrogen (BUN) (0 - 14.3 mmol/L) , high creatinine (0 – 154 mmol/L), low albumin (27.0 - 48.0 g/L), low and high chloride (95 – 115 mmol/L), low potassium (3.0 - 6.0 mmol/L), low sodium (130 – 150 mmol/L), high calcium (2.00 - 2.90 mmol/L), low and high phosphate (0.75 - 1.60 mmol/L).</description>
          <population>Safety Population: All participants who were randomized and had at least one dose of study drug, whether withdrawn prematurely or not, and who had at least one follow-up data point. Only participants with data available for the indicated laboratory abnormality were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="465"/>
                <count group_id="O2" value="448"/>
                <count group_id="O3" value="469"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit - High, n = 453, 433, 456</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit - low, n = 453, 433, 456</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin - High, n = 453, 433, 456</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin - Low n = 453, 433, 456</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets - High, n = 452, 431, 455</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets - Low, n = 452, 431, 455</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC - High, n = 453, 433, 456</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC - Low, n = 453, 433, 456</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT (SGPT) - High, n = 453, 434, 456</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN - High, n = 453, 434, 456</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine - High, n = 453, 434, 456</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin - Low, n = 453, 434, 456</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride – High, n = 453, 433, 456</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride – Low, n = 453, 433, 456</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium – Low, n = 453, 433, 456</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium – Low, n = 453, 433, 456</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium – High, n = 453, 434, 456</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate - High, n = 453, 434, 456</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate - Low, n = 453, 434, 456</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 2 years</time_frame>
      <desc>SAEs and non-serious AEs were reported for members of the safety population, comprised of participants who were randomized and had at least one dose of study drug, whether withdrawn prematurely or not, and who had at least one follow-up data point.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ibandronate 2.5mg Daily</title>
          <description>Participants received 2.5 milligrams (mg) of ibandronate orally daily and IV placebo injection at intervals of either 2 or 3 months for a total treatment period of 24 months.</description>
        </group>
        <group group_id="E2">
          <title>Ibandronate 2mg q 2 mo IV</title>
          <description>Participants received 2 mg of ibandronate intravenously (IV) every two months and placebo tablet daily for a total treatment period of 24 months.</description>
        </group>
        <group group_id="E3">
          <title>Ibandronate 3mg q 3 mo IV</title>
          <description>Participants received 3 mg of ibandronate IV every three months and placebo tablet daily for a total treatment period of 24 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 8.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Mitral valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Toxic nodular goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Hypotony of eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Retinal artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Retinal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Colonic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Postoperative infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Postoperative constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Radiation injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Red blood cell sedimentation rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus non-insulin-dependent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Bunion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Myelofibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Neuroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Non-hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Cerebellar syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Cerebral circulatory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Reversible ischaemic neurological deficit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Spinal vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Temporal lobe epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Histrionic personality disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Stress incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Fallopian tube cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Vaginal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioneurotic oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 8.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="301" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="316" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="284" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="469"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="465"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="448"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="469"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roche Trial Information Hotline</name_or_title>
      <organization>F. Hoffmann-La Roche AG</organization>
      <phone>+41 616878333</phone>
      <email>global.trial_information@roche.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

